- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06558825
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women With Trauma-related Conditions
Desarrollo y prueba piloto de una intervención de aceptación y cumplimiento de la PrEP en una clínica de salud mental para mujeres en tratamiento por afecciones relacionadas con traumas
The investigators have previously developed an integrated bio-behavioral intervention to promote PrEP uptake and adherence in cisgender women who are undergoing treatment for trauma-related mental health conditions and who are at a higher risk for HIV. The intervention is delivered within the mental health treatment setting and integrates knowledge, behavioral skills, and motivation to engage in and adhere to PrEP care. The purpose of this study is to assess the preliminary efficacy, feasibility, and acceptability of this intervention. The hypothesis is that, compared to standard treatment, the intervention will be feasible, acceptable, and associated with greater PrEP uptake and adherence.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The new integrated intervention will include motivational counseling guided by the Information Motivation-Behavioral Skills Model (IMB) which seeks to influence behavior change via information sharing, increasing motivation for change, and teaching behavioral skills to increase self-efficacy. This novel intervention will be delivered remotely using the emocha Mobile Health smartphone application. We expect that, compared to standard SUD treatment only, the integrated intervention will be associated with higher rates of PrEP uptake and adherence.This study will 1) Collect information on knowledge and attitudes about PrEP use and obtain feedback about the potential design of the integrated behavioral intervention from women undergoing treatment for trauma-related conditions who are at risk for HIV and their providers; 2) Develop an integrated behavioral intervention to promote PrEP uptake and adherence in women undergoing treatment for trauma-related conditions who are at high risk for HIV, and 3) Assess feasibility, acceptability and initial efficacy of the intervention.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77054
- Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Currently undergoing mental health treatment;
- Have a history of trauma;
- HIV negative;
- Sexually active with an opposite sex partner within the past 6 months;
- Not using PrEP for HIV prevention at the time of screening;
- Eligible for PrEP based on having at least one Centers for Disease Control and Prevention (CDC)-defined criteria for PrEP;
- Fluent in English;
- Own or have regular access to a smart phone.
Exclusion Criteria:
- HIV positive;
- Concurrently participating in another HIV prevention program;
- Have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy;
- Have psychological distress that would prohibit them from participating in the study;
- Be unable or unwilling to meet study requirements.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Intervención integrada para promover la adopción de PrEP
|
Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting. |
|
Comparador activo: Condición de tratamiento estándar
|
Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants who uptake PrEP
Periodo de tiempo: 12 weeks post intervention
|
PrEP uptake is defined as obtaining a prescription and taking the first dose. |
12 weeks post intervention
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Viabilidad de la intervención evaluada por el número de sesiones a las que asistieron los participantes
Periodo de tiempo: 15 semanas después de la inscripción
|
15 semanas después de la inscripción
|
|
|
Number of Participants who adhere to PrEP
Periodo de tiempo: 12 weeks post PrEP initiation
|
PrEP adherence is lab confirmed and is defined as having adequate levels of tenofovir (TFV) (>1000ng/ml). |
12 weeks post PrEP initiation
|
|
PrEP adherence as assessed by proportion of videos uploaded
Periodo de tiempo: from the time of PrEP initiation to 12 weeks post PrEP initiation
|
In the intervention arm, participants are asked to take a video of themselves taking PrEP. Videos are uploaded through an app, which is offered in the intervention arm only (and not the standard treatment arm). Data will be reported as the number of days a video is uploaded divided by the number of days of the intervention period. |
from the time of PrEP initiation to 12 weeks post PrEP initiation
|
|
PrEP adherence as assessed by proportion of self-reported daily adherence
Periodo de tiempo: from the time of PrEP initiation to 12 weeks post PrEP initiation
|
In both arms, participants are sent a questionnaires weekly in which they record the number of days they took PrEP over the past seven days. Data will be reported as the number of days PrEP is taken divided by the number of days of the intervention period. |
from the time of PrEP initiation to 12 weeks post PrEP initiation
|
|
Intervention feasibility as assessed by number of participants enrolled
Periodo de tiempo: at the time of enrollment
|
The number enrolled is the number of participants who signed the consent form. |
at the time of enrollment
|
|
Intervention feasibility as assessed by study retention
Periodo de tiempo: 15 weeks post enrollment
|
Study retention is assessed by the the number of participants who completed the study. |
15 weeks post enrollment
|
|
Intervention acceptability as assessed by score on a satisfaction questionnaire
Periodo de tiempo: 15 weeks post enrollment
|
This is a 15 item questionnaire and each item is scored from 1 (not at all true) to 9 (absolutely true). Total score ranges from 15 to 135, with a higher score indicating greater satisfaction. |
15 weeks post enrollment
|
|
Change in PrEP Anticipated Stigma as assessed by the PrEP Anticipated Stigma Scale
Periodo de tiempo: baseline, 15 weeks post enrollment
|
Total score ranges from 8 to 32, with a higher score indicating greater stigma. |
baseline, 15 weeks post enrollment
|
|
Change in perceived HIV risk as assessed by Perceived Risk of HIV Scale
Periodo de tiempo: baseline, 15 weeks post enrollment
|
Total score ranges from 10 to 40, with a higher score indicating a greater perceived HIV risk. |
baseline, 15 weeks post enrollment
|
|
Change in PrEP knowledge as assessed by PrEP Knowledge Questionnaire
Periodo de tiempo: baseline, 15 weeks post enrollment
|
Total score ranges from 0 to 6, with a higher score indicating a greater knowledge about PrEP. |
baseline, 15 weeks post enrollment
|
|
Change in PrEP attitudes as assessed by PrEP Attitudes Measure
Periodo de tiempo: baseline, 15 weeks post enrollment
|
Total score ranges from 5.2 to 26, with a higher score indicating a better attitude toward PrEP. |
baseline, 15 weeks post enrollment
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Angela Heads, PhD, The University of Texas Health Science Center, Houston
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- HSC-MS-21-0544
- 1R34DA055496-01 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .